Xcout Intel
Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Falls Church, Virginia, focused on optimizing blood pressure and cardiovascular health.
Subscribe to see Retension Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Retension Pharmaceuticals, Inc. at a glance
Retension Pharmaceuticals, Inc. is a company headquartered in United States. Its most recent funding round, Series A, raised $15M in August 2025. Xcout tracks 6 named people at Retension Pharmaceuticals, Inc., including Eric Keller (President).
Retension Pharmaceuticals, Inc. leadership
- Eric KellerPresident
- Dr. Bill SasielaChief Medical Officer
- Dr. Paul SweetnamChief Scientific Officer and Co-Founder
- Eric KellerExecutive Officer
- Donald OldsDirector
- Michael BerendtDirector
Retension Pharmaceuticals, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $15M | 1 named | |
| SEC Form D filing | $12.3M | — | |
| Series A | $10.4M | 1 named | |
| SEC Form D filing | $10.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Retension Pharmaceuticals, Inc. competitors
A few of Retension Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
Cardurion Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Burlington, Massachusetts, focused on discovering and developing novel therapeutics for cardiovascular diseases.
Response Pharmaceuticals, Inc. is a clinical-stage company based in Falls Church, Virginia, focused on weight management and metabolic health. The company develops pharmaceutical candidates such as RDX-002.
Proteon Therapeutics, Inc. is a biopharmaceutical company headquartered in Waltham, Massachusetts, dedicated to developing pharmaceuticals to address the medical needs of patients suffering from renal and vascular diseases.
Imbria Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel cardiovascular therapies.
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Armetheon, Inc. is a cardiovascular-focused, late-clinical stage specialty pharmaceutical company headquartered in Santa Clara, California, that develops and commercializes innovative medicines.
Get Retension Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Retension Pharmaceuticals, Inc. in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access